ClinicalTrials.gg
CompletedNCT01030679Updated Dec 16, 2009

Evaluate the Glycemic Control of CKD-501 in Type 2 Diabetes Mellitus

A Phase 2 interventional study of CKD-501 0.5mg and CKD-501 1mg in Diabetes Mellitus, Type 2, sponsored by Chong Kun Dang Pharmaceutical. Completed at 8 sites in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2009-12-16.

Sponsored by Chong Kun Dang Pharmaceutical · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
214
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies testing lobeglitazone in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. lobeglitazone · Diabetes Mellitus, Type 2.

Enrollment
5th of 23
214 · median 41
Started
2007
the only one that year
Phase 2
Only one
of the 23
Registered
2nd of 23
by date
Lead sponsor
20 of 23
Chong Kun Dang Pharmaceutical

Among the 23 studies testing lobeglitazone in Diabetes Mellitus, Type 2, this one is the 5th largest by enrollment, is the only one that started in 2007, is the only one in phase 2, and was the 2nd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 23 studies testing lobeglitazone in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

Where they have run

About lobeglitazone

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 23 studies testing lobeglitazone in Diabetes Mellitus, Type 2 as a file.
02

Study summary

The purpose of this study is to assess the safety and effectiveness of three doses of CKD-501 compared to placebo in lowering fasting plasma glucose levels in people with type 2 diabetes for 8 weeks.

03

Conditions studied

  • Diabetes Mellitus, Type 2

Keywords

  • Diabetes Mellitus, type 2
  • Glitazone
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type Ⅱ diabetes mellitus
  • Fasting Plasma Glucose(FPG)≥ 126 and ≤ 270
  • between 7 and 11%
  • (BMI) in the range 21-40
  • The patients who has been taking oral hypoglycemic agent or diet therapy before minimum 1 month
  • Agreement with written

Exclusion criteria

Exclusion Criteria:

  • Type I diabetes, gestational diabetes or secondary diabetes
  • Treatment with insulin(over 1month) within 3 months
  • Fasting Plasma Glucose level is over 270 mg/dl
  • Triglyceride level is 500 mg/dl and over
  • Uncontrollable hypertension
  • History of myocardial infarction, heart failure, cerebral infarction, hematencephalon or unstable angina within 6 months
  • Severe hepatic dysfunction: , ALT, Total , ALP level over or equal to 3 times as high as upper normal limit(UNL)
  • Severe renal dysfunction: Renal failure or serum creatinine greater than 30% normal limit
  • Needs treatment for acute disease, uncontrolled other diseae or diabetic complications
  • In treatment concomitant drug having severe risk drug interaction with drug
  • History of cancer within 5 years
  • History of drug abuse or alcoholism
  • Antigen(HBsAg) test is positive
  • Treatment systemic or inhalant within 1 month prior to Screening
  • Patient who have experience such as reaction, serious adverse event or no effect by treatment with glitazones
  • Fertile women who not practice with appropriate methods Pregnant women or nursing mothers
  • Has a to treatment investigational drug from the medical and psychogenic side
  • Participated in other trial within 4 weeks Participating in other trial at present
  • An impossible one who participates in clinical trial by legal or investigator's decision
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
214 participants (actual)

Study arms

  • Experimental
    CKD-501 0.5mg

    Drug: CKD-501 0.5mg

  • Experimental
    CKD-501 1mg

    Drug: CKD-501 1mg

  • Experimental
    CKD-501 2mg

    Drug: CKD-501 2mg

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • 0.5 mg/tablet, orally, 1 tablet once daily for 8 weeks

    Also known as: Lobeglitazone

  • 1 mg/tablet, orally, 1 tablet once daily for 8 weeks

    Also known as: Lobeglitazone

  • 2 mg/tablet, orally, 1 tablet once daily for 8 weeks

    Also known as: Lobeglitazone

  • DrugPlacebo

    orally, 1 tablet once daily for 8 weeks

06

What researchers measure

Primary outcomes

  1. Change from baseline in fasting plasma glucose at 8 weeks

    Time frame: 8 weeks

Secondary outcomes

  1. Change from baseline in Glycemic parameters after 8 weeks

    Time frame: 8 weeks

  2. Change from baseline in Lipid parameters after 8 weeks

    Time frame: 8 weeks

  3. Adverse event profile after 8 weeks of treatment

    Time frame: 8 weeks

07

Study locations

8 sites
  • The Inje University Medical Center
    Busan, Korea, Republic of
  • The Yeungnam University Hospital
    Daegu, Korea, Republic of
  • The Chtholic University of Korea Uijeongbu St. Mary's Hospital
    Gyeonggi-do, Korea, Republic of
  • The Seoul National Univertisy Bundang Hospital
    Gyeonggi-do, Korea, Republic of
  • The Wonju Christian Hospital
    Kangwon-Do, Korea, Republic of
  • The Inje University Sanggye-Paik Hospital
    Seoul, Korea, Republic of
  • The Korea University Anam Hospital
    Seoul, Korea, Republic of
  • The Samsung Medical Center
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2007, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2009
First posted
Dec 11, 2009
Start
Jul 2007
Primary completionActual
Oct 2008
CompletionActual
Oct 2008
Last update
Dec 16, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01030679
First posted
Dec 11, 2009
Start date
Jul 2007
Primary completion
Oct 2008
Completion
Oct 2008
Last update
Dec 16, 2009

Study contacts

Dongseop Choi, MD.,Ph.D.
study chair · The Korea University Anam Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lobeglitazone

Start the discussion